Research Article
Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses
Sheila Laverty,
John D. Sandy,
Christophe Celeste,
Pascal Vachon,
Jean-Francois Marier,
Anna H. K. Plaas,
Sheila Laverty
Faculté de Médicine Vétérinaire, Université de Montréal, Montreal, Quebec, Canada
Search for more papers by this authorJohn D. Sandy
University of South Florida, and Shriners Hospital for Children, Tampa, Florida
Search for more papers by this authorChristophe Celeste
Faculté de Médicine Vétérinaire, Université de Montréal, Montreal, Quebec, Canada
Search for more papers by this authorPascal Vachon
Faculté de Médicine Vétérinaire, Université de Montréal, Montreal, Quebec, Canada
Search for more papers by this authorJean-Francois Marier
MDS Pharma Services, Montreal, Quebec, Canada
Search for more papers by this authorCorresponding Author
Anna H. K. Plaas
University of South Florida, Tampa
Department of Internal Medicine, University of South Florida, COM, 12901 Bruce B. Downs Boulevard, MDC 19, Tampa, FL 33612Search for more papers by this authorSheila Laverty,
John D. Sandy,
Christophe Celeste,
Pascal Vachon,
Jean-Francois Marier,
Anna H. K. Plaas,
Sheila Laverty
Faculté de Médicine Vétérinaire, Université de Montréal, Montreal, Quebec, Canada
Search for more papers by this authorJohn D. Sandy
University of South Florida, and Shriners Hospital for Children, Tampa, Florida
Search for more papers by this authorChristophe Celeste
Faculté de Médicine Vétérinaire, Université de Montréal, Montreal, Quebec, Canada
Search for more papers by this authorPascal Vachon
Faculté de Médicine Vétérinaire, Université de Montréal, Montreal, Quebec, Canada
Search for more papers by this authorJean-Francois Marier
MDS Pharma Services, Montreal, Quebec, Canada
Search for more papers by this authorCorresponding Author
Anna H. K. Plaas
University of South Florida, Tampa
Department of Internal Medicine, University of South Florida, COM, 12901 Bruce B. Downs Boulevard, MDC 19, Tampa, FL 33612Search for more papers by this authorAbstract
Objective
To examine the concentration of glucosamine in the synovial fluid and its pharmacokinetics in serum in a large animal model following dosing with glucosamine HCl at clinically relevant levels.
Methods
Eight adult female horses were studied. After an overnight fast, glucosamine HCl (20 mg/kg of body weight) was administered by either nasogastric (NG) intubation or intravenous (IV) injection. Blood samples were collected before dosing and at 5, 15, 30, 60, 120, 180, 240, 360, 480, and 720 minutes after dosing. Synovial fluid samples were collected from the radiocarpal joints 48 hours before dosing and at 1 and 12 hours after dosing. Glucosamine was assayed by fluorophore-assisted carbohydrate electrophoresis.
Results
The maximum concentration of glucosamine in serum reached ∼300 μM (∼50 μg/ml) following IV dosing and ∼6 μM (∼1 μg/ml) following NG dosing. Synovial fluid concentrations reached 9–15 μM with IV dosing and 0.3–0.7 μM with NG dosing, and remained elevated (range 0.1–0.7 μM) in most animals even at 12 hours after dosing. Following NG dosing, the median serum maximal concentration of 6.1 μM (range 4.38–7.58) was attained between 30 minutes and 4 hours postdose. The mean apparent volume of distribution was 15.4 liters/kg, the mean bioavailability was 5.9%, and the mean elimination half-life was 2.82 hours.
Conclusion
Clinically relevant dosing of glucosamine HCl in this large monogastric animal model results in serum and synovial fluid concentrations that are at least 500-fold lower than those reported to modify chondrocyte anabolic and catabolic activities in tissue and cell culture experiments. We conclude that the apparent therapeutic benefit of dietary glucosamine on pain and joint space width in humans and animals may be secondary to its effects on nonarticular tissues, such as the intestinal lining, liver, or kidney, since these may be exposed to much high levels of glucosamine following ingestion.
REFERENCES
- 1 Bruyere O, Pavelka K, Rovati LC, Deroisy R, Olejarova M, Gatterova J, et al. Glucosamine sulfate reduces osteoarthritis progression in postmenopausal women with knee osteoarthritis: evidence from two 3-year studies. Menopause 2004; 11: 138–43.
- 2 Christgau S, Henrotin Y, Tanko LB, Rovati LC, Collette J, Bruyere O, et al. Osteoarthritic patients with high cartilage turnover show increased responsiveness to the cartilage protecting effects of glucosamine sulphate. Clin Exp Rheumatol 2004; 22: 36–42.
- 3 McAlindon TE, LaValley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA 2000; 283: 1469–75.
- 4 Towheed TE, Anastassiades TP, Shea B, Houpt J, Welch V, Hochberg MC. Glucosamine therapy for treating osteoarthritis [review]. Cochrane Database Syst Rev 2001; 1: CD002946.
- 5 Richy F, Bruyere O, Ethgen O, Cucherat M, Henrotin Y, Reginster JY. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003; 163: 1514–22.
- 6 Towheed TE. Published meta-analyses of pharmacological therapies for osteoarthritis. Osteoarthritis Cartilage 2002; 10: 836–7.
- 7 Blakeley JA, Ribeiro V. A survey of self-medication practices and perceived effectiveness of glucosamine products among older adults. Complement Ther Med 2002; 10: 154–60.
- 8 Reginster JY, Bruyere O, Lecart MP, Henrotin Y. Naturocetic (glucosamine and chondroitin sulfate) compounds as structure-modifying drugs in the treatment of osteoarthritis. Curr Opin Rheumatol 2003; 15: 651–5.
- 9 Matheson AJ, Perry CM. Glucosamine: a review of its use in the management of osteoarthritis. Drugs Aging 2003; 20: 1041–60.
- 10 Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002; 162: 2113–23.
- 11 Oegema TR Jr, Deloria LB, Sandy JD, Hart DA. Effect of oral glucosamine on cartilage and meniscus in normal and chymopapain-injected knees of young rabbits. Arthritis Rheum 2002; 46: 2495–503.
- 12 Setnikar I, Giachetti C, Zanolo G. Absorption, distribution and excretion of radioactivity after a single intravenous or oral administration of [14C] glucosamine to the rat. Pharmatherapeutica 1984; 3: 538–50.
- 13 Setnikar I, Giacchetti C, Zanolo G. Pharmacokinetics of glucosamine in the dog and in man. Arzneimittelforschung 1986; 36: 729–35.
- 14 Setnikar I, Palumbo R, Canali S, Zanolo G. Pharmacokinetics of glucosamine in man. Arzneimittelforschung 1993; 43: 1109–13.
- 15 Aghazadeh-Habashi A, Sattari S, Pasutto F, Jamali F. Single dose pharmacokinetics and bioavailability of glucosamine in the rat. J Pharm Pharm Sci 2002; 5: 181–4.
- 16 Du J, White N, Eddington ND. The bioavailability and pharmacokinetics of glucosamine hydrochloride and chondroitin sulfate after oral and intravenous single dose administration in the horse. Biopharm Drug Dispos 2004; 25: 109–16.
- 17 Plaas AH, West L, Midura RJ, Hascall VC. Disaccharide composition of hyaluronan and chondroitin/dermatan sulfate: analysis with fluorophore-assisted carbohydrate electrophoresis. Methods Mol Biol 2001; 171: 117–28.
- 18 Plaas AH, West LA, Midura RJ. Keratan sulfate disaccharide composition determined by FACE analysis of keratanase II and endo-β-galactosidase digestion products. Glycobiology 2001; 11: 779–90.
- 19 Calabro A, Midura R, Wang A, West L, Plaas A, Hascall VC. Fluorophore-assisted carbohydrate electrophoresis (FACE) of glycosaminoglycans. Osteoarthritis Cartilage 2001; 9: S16–22.
- 20 Rowland M, McLachlan A. Pharmacokinetic considerations of regional administration and drug targeting: influence of site of input in target tissue and flux of binding protein. J Pharmacokinet Biopharm 1996; 24: 369–87.
- 21 Dyke TM, Hubbell JA, Sams RA, Hinchcliff KW. Hepatic blood flow in horses during the recuperative period from maximal exercise. Am J Vet Res 1998; 59: 1476–80.
- 22 Kearns CF, McKeever KH, John-Alder H, Abe T, Brechue WF. Relationship between body composition, blood volume and maximal oxygen uptake. Equine Vet J Suppl 2002: 485–90.
- 23 Adebowale A, Du J, Liang Z, Leslie JL, Eddington ND. The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs. Biopharm Drug Dispos 2002; 23: 217–25.
- 24 Dyer J, Fernandez-Castano Merediz E, Salmon KS, Proudman CJ, Edwards GB, Shirazi-Beechey SP. Molecular characterisation of carbohydrate digestion and absorption in equine small intestine. Equine Vet J 2002; 34: 349–58.
- 25 Bochner F, Williams DB, Morris PM, Siebert DM, Lloyd JV. Pharmacokinetics of low-dose oral modified release, soluble and intravenous aspirin in man, and effects on platelet function. Eur J Clin Pharmacol 1988; 35: 287–94.
- 26 Liao WC, Vesterqvist O, Delaney C, Jemal M, Ferreira I, Ford N, et al. Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects. Br J Clin Pharmacol 2003; 56: 395–406.
- 27 Werner U, Werner D, Pahl A, Mundkowski R, Gillich M, Brune K. Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry. Biomed Chromatogr 2002; 16: 56–60.
- 28 Uldry M, Ibberson M, Hosokawa M, Thorens B. GLUT2 is a high affinity glucosamine transporter. FEBS Lett 2002; 524: 199–203.
- 29 Levick JR. Microvascular architecture and exchange in synovial joints. Microcirculation 1995; 2: 217–33.
- 30 Sweeney C, Mackintosh D, Mason RM. UDP-sugar metabolism in Swarm rat chondrosarcoma chondrocytes. Biochem J 1993; 290: 563–70.
- 31 Mroz PJ, Silbert JE. Effects of [3H]glucosamine concentration on [3H]chondroitin sulphate formation by cultured chondrocytes. Biochem J 2003; 376: 511–5.
- 32 Sandy JD, Gamett D, Thompson V, Verscharen C. Chondrocyte-mediated catabolism of aggrecan: aggrecanase-dependent cleavage induced by interleukin-1 or retinoic acid can be inhibited by glucosamine. Biochem J 1998; 335: 59–66.
- 33 Setnikar I, Rovati LC. Absorption, distribution, metabolism and excretion of glucosamine sulfate: a review. Arzneimittelforschung 2001; 51: 699–725.
- 34 Windhaber RA, Wilkins RJ, Meredith D. Functional characterisation of glucose transport in bovine articular chondrocytes. Pflugers Arch 2003; 446: 572–7.
- 35 Giraud I, Rapp M, Maurizis JC, Madelmont JC. Application to a cartilage targeting strategy: synthesis and in vivo biodistribution of 14C-labeled quaternary ammonium-glucosamine conjugates. Bioconjug Chem 2000; 11: 212–8.
- 36 Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001; 357: 251–6.
- 37 Kim JJ, Conrad HE. Effect of D-glucosamine concentration on the kinetics of mucopolysaccharide biosynthesis in cultured chick embryo vertebral cartilage. J Biol Chem 1974; 249: 3091–7.
- 38 Kleine TO, Baumann HJ. In-vivo biosynthesis of acid glycosaminoglycans with radiosulfate and [3H]glucosamine in single joints from rats of different age. Z Gerontol 1990; 23: 123–5.
- 39 Thonar EJ, Buckwalter JA, Kuettner KE. Maturation-related differences in the structure and composition of proteoglycans synthesized by chondrocytes from bovine articular cartilage. J Biol Chem 1986; 261: 2467–74.
- 40 Morales TI, Hascall VC. Factors involved in the regulation of proteoglycan metabolism in articular cartilage. Arthritis Rheum 1989; 32: 1197–201.
- 41 Noyszewski EA, Wroblewski K, Dodge GR, Kudchodkar S, Beers J, Sarma AV, et al. Preferential incorporation of glucosamine into the galactosamine moieties of chondroitin sulfates in articular cartilage explants. Arthritis Rheum 2001; 44: 1089–95.
- 42 Gouze JN, Bianchi A, Becuwe P, Dauca M, Netter P, Magdalou J, et al. Glucosamine modulates IL-1-induced activation of rat chondrocytes at a receptor level, and by inhibiting the NF-κ B pathway. FEBS Lett 2002; 510: 166–70.
- 43 Dodge GR, Jimenez SA. Glucosamine sulfate modulates the levels of aggrecan and matrix metalloproteinase-3 synthesized by cultured human osteoarthritis articular chondrocytes. Osteoarthritis Cartilage 2003; 11: 424–32.
- 44 Byron CR, Orth MW, Venta PJ, Lloyd JW, Caron JP. Influence of glucosamine on matrix metalloproteinase expression and activity in lipopolysaccharide-stimulated equine chondrocytes. Am J Vet Res 2003; 64: 666–71.
- 45 Rumberger JM, Wu T, Hering MA, Marshall S. Role of hexosamine biosynthesis in glucose-mediated up-regulation of lipogenic enzyme mRNA levels: effects of glucose, glutamine, and glucosamine on glycerophosphate dehydrogenase, fatty acid synthase, and acetyl-CoA carboxylase mRNA levels. J Biol Chem 2003; 278: 28547–52.
- 46 Zhang P, Klenk ES, Lazzaro MA, Williams LB, Considine RV. Hexosamines regulate leptin production in 3T3-L1 adipocytes through transcriptional mechanisms. Endocrinology 2002; 143: 99–106.
- 47 Han DH, Chen MM, Holloszy JO. Glucosamine and glucose induce insulin resistance by different mechanisms in rat skeletal muscle. Am J Physiol Endocrinol Metab 2003; 285: E1267–72.
- 48 Vosseller K, Sakabe K, Wells L, Hart GW. Diverse regulation of protein function by O-GlcNAc: a nuclear and cytoplasmic carbohydrate post-translational modification. Curr Opin Chem Biol 2002; 6: 851–7.
- 49 Kamemura K, Hart GW. Dynamic interplay between O-glycosylation and O-phosphorylation of nucleocytoplasmic proteins: a new paradigm for metabolic control of signal transduction and transcription. Prog Nucleic Acid Res Mol Biol 2003; 73: 107–36.
- 50 Konrad RJ, Kudlow JE. The role of O-linked protein glycosylation in β-cell dysfunction. Int J Mol Med 2002; 10: 535–9.
- 51
Milewski S.
Glucosamine-6-phosphate synthase: the multi-facets enzyme.
Biochim Biophys Acta
2002;
1597:
173–92.
10.1016/S0167-4838(02)00318-7 Google Scholar
- 52 Thorens B. Glucose transporters in the regulation of intestinal, renal, and liver glucose fluxes. Am J Physiol 1996; 270: G541–53.
- 53 Wilson JE. Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J Exp Biol 2003; 206: 2049–57.
- 54 Gabriely I, Yang XM, Cases JA, Ma XH, Rossetti L, Barzilai N. Hyperglycemia modulates angiotensinogen gene expression. Am J Physiol Regul Integr Comp Physiol 2001; 281: R795–802.
- 55 Hsieh TJ, Fustier P, Zhang SL, Filep JG, Tang SS, Ingelfinger JR, et al. High glucose stimulates angiotensinogen gene expression and cell hypertrophy via activation of the hexosamine biosynthesis pathway in rat kidney proximal tubular cells. Endocrinology 2003; 144: 4338–49.
- 56 Skillman JM, Ahmed OA, Rowsell AR. Incidental improvement of breast capsular contracture following treatment of arthritis with glucosamine and chondroitin [letter]. Br J Plast Surg 2002; 55: 454.
- 57 Dawson PA, Markovich D. Transcriptional regulation of the sodium-sulfate cotransporter NaS(i)-1 gene. Cell Biochem Biophys 2002; 36: 175–82.
- 58 Hoffer LJ, Kaplan LN, Hamadeh MJ, Grigoriu AC, Baron M. Sulfate could mediate the therapeutic effect of glucosamine sulfate. Metabolism 2001; 50: 767–70.
